>Cirugía y Cirujanos
>Year 2004, Issue 1
Bravo-Topete EG ,Mendoza-Hernández F, Cejudo-Álvarez J, Briones-Garduño C
Cabergoline for inhibition of lactation
Cir Cir 2004; 72 (1)
PDF: 70.43 Kb.
Introduction: Despite advances in prevention inhibition of lactation,
only administration of strogens or these combined with androgens show variable
effectiveness and are indirectly associated with high percentage for lactation
rebound, thrombosis, or pulmonary embolism or both of the later during puerperium;
in addition, bromocriptine, also used indirectly for inhibition of lactation,
is associated with lactation, rebound in 18-40%. Cabergolin is a new ergoline
with efficient and durable prolactin reducer effect with fewer adverse effects.
Problem: Which will the smallest cabergolin dosage be to inhibit lactation?
Objective: To demonstrate clinical effectiveness with smallest cabergolina
dosage in lactation inhibition.
Material and methods: We carried on a the Service Clinical test on patients
hospitalization with an indication to inhibit lactation as the Hospital of Gynecology
and Obstetrics, Infantil Maternal Institute of the State of Mexico (IMIEM).
The study was done 80 patients to who we administered oral 0.5 mg cabergoline
to 40 patients and another group of 40 whom we administered 1.0 mg of cabergoline
orally at random and blinded by means of out-patient consultation. We studied
correlation between dose and inhibition of lactation as well as presence of
Results: In the group of patients to whom administered 0.5 mg, we found
65% (n = 26) with lactation inhibition; adverse effects in this group appeared
in 32.5% (n = 13) the second group with a dose of 1.0 mg; 95% with adverse effects
in 25% P < 0.001.
Conclusions: Inhibition of lactation with unique dose of 1.0 has satisfactory
clinical effectiveness, tus being the smaller dose to inhibit lactation at a
||Cabergoline, Inhibition of lactation.
European Multicentre Study Group for Cabergoline in Lactation Inhibition. Single dose cabergolina versus bromocriptine in inhibition of puerperal lactation; randomized, double blind, multicentre study. Br Med J 1991;302:1367-1371.
Vance ML. Prolactin: hyperprolactinemic syndromes and management. In: Endocrinology. 2nd London: W.B. Saunders, 1998. pp.408-409.
Dalkin AC. Medical therapy of hyperprolactinaemia. Endocrinol Metabol Clin North Am 1989;18:259-276.
Crosignari PG. Dopaminergic treatments for hyperprolactinaemia. Clin Obstet Gynecol 1990;4:441-445.
Mekki MO. The problem of prolactinoma. Saudi Med J 1988;9:546-557.
Brambilla E. Synthesis and nidation inhibitory activity of a new class of ergoline derivaties. Eur J Med Chem 1989;24:421-426.
Philosophe R. Novel approaches to the management of hyperprolactinaemia. Obstet Gynecol 1991;3:336-342.
Pontiroli AE. Inhibition of basal and metoclopramide-induced prolactin release by cabergoline, an extremely long-acting dopaminergic drug. J Clin Endocrinol Metabol 1987;65:1057-1059.
Ferrari C. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist in hyperprolactinemic patients. J Clin Endocrinol Metabol 1986;63:941-945.
Mattei AM. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline and two dose levels in hyperprolactinemic patients. J Clin Endocrinol Metabol 1988;66: 193-198.
Cocchiara G. Excretion balance and urinary metabolic pattern of cabergoline in man. Drug Metabol Drug Interac 1992;10:199-211.
Bertin D. Urinary kinetics and relative bioavailability of cabergoline after oral administration to healthy female volunteers. Study No. FCE 21336/609, 1990.
Ganong WK. Review of medical physiology. 14th ed. New York, London: Lange Medical/McGraw, Hill. 1989;204:385-386.
Benker G. Control of prolactin secretion. Klinische W 1990;68:1157-1167.
Thurn JR. HIV worldwide. What has happened? What has changed? Postgrad Med 1992;91:99-113.
Atkinson HC. Guide to safety of drugs in human milk. 2nd ed. Clinical Pharmacokinetics Drug Data Handbook; 1990. pp.150-154.
Caballero Gordo A. Oral cabergoline. Single dosis inhibition of puerperal lactation. J Reproductive Med 1991;36:712-721.
Sartorio A. Osteocalcin levels in patients with micro-prolactinoma before and during medical treatment. J Endocrinol Invest 1990;13: 419-422.
>Cirugía y Cirujanos
>Year 2004, Issue 1